Skip to main content
SpringerLink
Log in

Cyclooxygenase-2, Prostaglandins, and Colorectal Carcinogenesis

  • Chapter
COX-2 Blockade in Cancer Prevention and Therapy

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 127 Accesses

Abstract

Despite significant progress in understanding the molecular basis of colorectal cancer, the disease remains a major global health problem that leads to approx 550,00 annual deaths worldwide. This failure in treatment has led to a search for novel, nontoxic agents that could possibly be utilized to prevent the development of the disease. Recently, inhibitors of the cyclooxygenase-2 (COX-2) enzyme have emerged as a class of drugs that may represent a viable approach for the chemoprevention of colorectal cancer. This chapter will begin with a review of some of the key findings that led to the hypothesis that COX-2 inhibitor therapy inhibits colorectal cancer development followed by a discussion of the prostaglandin (PG) signaling pathways that have been linked to the carcinogenic process.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Herschman HR. Prostaglandin synthase 2. BBA 1996; 1299: 125–140.

    Article  Google Scholar 

  2. DuBois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE. Cyclooxygenase in biology and disease. FASEB J 1998; 12: 1063–1073.

    PubMed  CAS  Google Scholar 

  3. Herschman HR, Xie W, Reddy S. Inflammation, reproduction, cancer and all that… The regulation and role of the inducible prostaglandin synthase. Bioessays 1995; 17: 1031–1037.

    Article  PubMed  CAS  Google Scholar 

  4. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000; 69: 145–182.

    Article  PubMed  CAS  Google Scholar 

  5. Raz A, Wyche A, Siegel N, Needleman P Regulation of fibroblast cyclooxygenase synthesis by interleukin-1 J Biol Chem 1988; 263: 3022–3028.

    PubMed  CAS  Google Scholar 

  6. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990; 265(28):16,737–16,740.

    Google Scholar 

  7. Xie W, Chipman J, Robertson D, Erikson R, Simmons D. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. ProcNatlAcad Sci USA 1991; 88: 2692–2696.

    Article  CAS  Google Scholar 

  8. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991; 266:12, 866–12, 872.

    Google Scholar 

  9. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996; 271(52):33,157–33,160.

    Google Scholar 

  10. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, et al. Selective inhibition of inducible cyclooxygenase-2 in vivo is antiinflammatory and nonulcerogenic. Proc NatlAcad Sci USA 1994; 91: 3228–3232.

    Article  CAS  Google Scholar 

  11. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999; 117: 776–783.

    Article  PubMed  CAS  Google Scholar 

  12. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999; 354: 2106–2111.

    Article  PubMed  CAS  Google Scholar 

  13. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983; 24: 83–87.

    Article  PubMed  CAS  Google Scholar 

  14. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121: 241–246.

    PubMed  CAS  Google Scholar 

  15. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, Speizer FE. Aspirin and the risk of colorectal cancer in women. N Eng J Med 1995; 333: 609–614.

    Article  CAS  Google Scholar 

  16. Thun MJ, Namboodiri MM, Heath CWJ. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593–1596.

    Article  PubMed  CAS  Google Scholar 

  17. DuBois RN, Giardiello FM, Smalley WE. Nonsteroidal anti-inflammatory drugs, eicosanoids and colorectal cancer prevention. Gastroenterol Clin North Amer 1996; 25: 773–791.

    Article  CAS  Google Scholar 

  18. Kinzler KW, Nilbert MC, Vogelstein B, Bryan TM, Levy DB, Smith KJ, et al. Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 1991; 251 (4999): 1366–1370.

    Article  PubMed  CAS  Google Scholar 

  19. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101 (3): 635–639.

    PubMed  CAS  Google Scholar 

  20. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal amd rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993; 80: 1618–1619.

    Article  PubMed  CAS  Google Scholar 

  21. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328: 1313 1316.

    Google Scholar 

  22. Steinbach G, Lynch PM, Phillips RKS, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946–1952.

    Article  PubMed  CAS  Google Scholar 

  23. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to mutiple intestinal neoplasia in the mouse. Science 1990; 247: 322–325.

    Article  PubMed  CAS  Google Scholar 

  24. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C. Multiple intestinal neoplasia caused by a mutation is the murine homolog of the APC gene. Science 1992; 256: 668–670.

    Article  PubMed  CAS  Google Scholar 

  25. Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996; 56: 2556–2560.

    PubMed  CAS  Google Scholar 

  26. Beazer-Barclay Y, Levy DB, Moser AR, Dove WF, Hamilton SR, Vogelstein B, Kinzler KW. Sulindac suppresses tumorigenesis the min mouse. Carcinogenesis 1996; 17: 1757–1760.

    Article  PubMed  CAS  Google Scholar 

  27. Jacoby RF, Marshall DJ, Newton MA, Novakovic K, Tutsch K, Cole CE, et al. Chemoprevention of spontaneous intestinal adenomas in the ApcM1D mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 1996; 56: 710–714.

    PubMed  CAS  Google Scholar 

  28. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000; 60 (18): 5040–5044.

    PubMed  CAS  Google Scholar 

  29. Oshima M, Murai N, Kargman S, Arguello M, Luk P, Kwong E, et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001; 61 (4): 1733–1740.

    PubMed  CAS  Google Scholar 

  30. Lijinsky W. Intestinal cancer induced by N-nitroso compounds. Toxicol Pathol 1988; 16 (2): 198–204.

    Article  PubMed  CAS  Google Scholar 

  31. Reddy BS, Rao CV, Rivenson A, Kelloff G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993; 14: 1493–1497.

    Article  PubMed  CAS  Google Scholar 

  32. Kawamori, T, Rao, CV, Seibert, K, Reddy, BS. (1998) Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58, 409–412.

    PubMed  CAS  Google Scholar 

  33. Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000; 60 (2): 293–297.

    PubMed  CAS  Google Scholar 

  34. Yoshimi N, Shimizu M, Matsunaga K, Yamada Y, Fujii K, Hara A, Mori H. Chemopreventive effect of N-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide (NS-398), a selective cyclooxygenase-2 inhibitor, in rat colon carcinogenesis induced by azoxymethane. Jpn J Cancer Res 1999; 90: 406–412.

    Article  PubMed  CAS  Google Scholar 

  35. Fukutake M, Nakatsugi S, Isoi T, Takahashi M, Ohta T, Mamiya S, et al. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice. Carcinogenesis 1998; 19: 1939–1942.

    Article  PubMed  CAS  Google Scholar 

  36. Goldman AP, Williams CS, Sheng H, Lamps LW, Williams VP, Pairet M, et al. Carcinogenesis 1998; 19: 2195–2199.

    Article  PubMed  CAS  Google Scholar 

  37. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey R, Morrow J, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997; 99: 2254–2259.

    Article  PubMed  CAS  Google Scholar 

  38. Williams CS, Watson M, Sheng H, Helou R, Shao J, DuBois RN. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 2000; 60: 6045–6051.

    PubMed  CAS  Google Scholar 

  39. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in APC6:716 knockout mice by inhibition of prostaglandin endoperoxide synthase-2 (COX-2). Cell 1996; 87: 803–809.

    Article  PubMed  CAS  Google Scholar 

  40. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000; 105: 1589–1594.

    Article  PubMed  CAS  Google Scholar 

  41. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000; 60 (17): 4705–4708.

    PubMed  CAS  Google Scholar 

  42. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001; 276(21):18,563–18,569.

    Google Scholar 

  43. Neufang G, Furstenberger G, Heidt M, Marks F, Muller-Decker K. Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin. Proc Natl Acad Sci USA 2000, in press.

    Google Scholar 

  44. Zhang X, Morham SG, Langenbach R, Young DA. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblast. JExp Med 1999; 190: 445–450.

    Article  Google Scholar 

  45. Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Bioch Pharm 1996; 52: 237–245.

    Article  CAS  Google Scholar 

  46. Yamamoto Y, Yin MJ, Lin KM, Gaynor RB. Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 1999; 274(38):27,307–27,314.

    Google Scholar 

  47. He TC, Chan TA, Vogelstein B, Kinzler KW. PPARS is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999; 99: 335–345.

    Article  PubMed  CAS  Google Scholar 

  48. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 2000; 290 (5493): 989–992.

    Article  PubMed  CAS  Google Scholar 

  49. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183–1188.

    PubMed  CAS  Google Scholar 

  50. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, et al. Expression of cyclooxygenase-1 and -2 in colorectal cancer. Cancer Res 1995; 55: 3785–3789.

    PubMed  CAS  Google Scholar 

  51. Kargman S, O’Neill G, Vickers P, Evans J, Mancini J, Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995; 55: 2556–2559.

    PubMed  CAS  Google Scholar 

  52. Williams CW, Luongo C, Radhika A, Zhang T, Lamps LW, Nanney LB, et al. Elevated cyclooxygenase-2 levels in Min mouse ademonas. Gastroenterology 1996; 111: 1134–1140.

    Article  PubMed  CAS  Google Scholar 

  53. DuBois RN, Radhika A, Reddy BS, Entingh AJ. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 1996; 110: 1259–1262.

    Article  PubMed  CAS  Google Scholar 

  54. Shao J, Sheng H, Aramandla R, Pereira MA, Lubet RA, Hawk E, et al. Coordinate regulation of cyclooxygenase-2 and TGF-betal in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis 1999; 20 (2): 185–191.

    Article  PubMed  CAS  Google Scholar 

  55. Kutchera W, Jones DA, Matsunami N, Groden J, McIntyre TM, Zimmerman GA, et al. Prostaglandin H synthase-2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci USA 1996; 93: 4816–4820.

    Article  PubMed  CAS  Google Scholar 

  56. Karnes WE, Shattuck-Brandt R, Burgart LJ, DuBois RN, Tester DJ, Cunningham JM, et al. Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res 1998; 58: 5473–5477.

    PubMed  CAS  Google Scholar 

  57. Shattuck-Brandt RL, Lamps LW, Heppner-Goss KJ, DuBois RN, Matrisian LM. Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms. Mol Carcinog 1999; 24: 177187.

    Google Scholar 

  58. Hull MA, Booth JK, Tisbury A, Scott N, Bonifer C, Markham AF, Coletta PL. Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice. Br J Cancer 1999; 79 (9–10): 1399–1405.

    Article  PubMed  CAS  Google Scholar 

  59. Shattuck-Brandt RL, Varilek GW, Radhika A, Yang F, Washington MK, DuBois RN. Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice. Gastroenterology 2000; 118 (2): 337–345.

    Article  PubMed  CAS  Google Scholar 

  60. Chapple KS, Cartwright EJ, Hawcroft G, Tisbury A, Bonifer C, Scott N, et al. Localization of cyclooxygenase-2 in human sporadic colorectal ademona. Am J Pathol 2000; 156: 545–553.

    Article  PubMed  CAS  Google Scholar 

  61. Bamba H, Ota S, Kato A, Adachi A, Itoyama S, Matsuzaki F. High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. Int J Cancer 1999; 83: 470–475.

    Article  PubMed  CAS  Google Scholar 

  62. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner MB, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306–1311.

    PubMed  CAS  Google Scholar 

  63. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell 1995; 83: 493–501.

    Article  PubMed  CAS  Google Scholar 

  64. Tsujii M, Kuwano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94: 3336–3340.

    Article  PubMed  CAS  Google Scholar 

  65. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hod M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705–716.

    Article  PubMed  CAS  Google Scholar 

  66. Majima M, Isono M, Ikeda Y, Hayashi I, Hatanaka K, Harada Y, et al. Significant roles of inducible cyclooxygenase (COX)-2 in angiogenesis in rat sponge implants. Jpn JPharmacol 1997; 75 (2): 105–114.

    Article  CAS  Google Scholar 

  67. Majima M, Hayashi I, Muramatsu M, Katada J, Yamashina S, Katori M. Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br J Pharmacol 2000; 130 (3): 641–649.

    Article  PubMed  CAS  Google Scholar 

  68. Daniel TO, Liu H, Morrow JD, Crews BC, Marnett LJ. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 1999; 59: 4574–4577.

    PubMed  CAS  Google Scholar 

  69. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh U, Tarnawski AS. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nature Med 1999; 5: 1418–1423.

    Article  PubMed  CAS  Google Scholar 

  70. Dormond O, Foletti A, Paroz C, Ruegg C. NSAIDS inhibit alphaVbeta3 integrin-mediated and Cdc42/ Rac-dependent endothelial-cell spreading, migration, and angiogenesis. Nature Med 2001; 9: 1041–1047.

    Google Scholar 

  71. Sugimoto Y, Narumiya S, Ichikawa A. Distribution and function of prostanoid receptors: studies from knockout mice. Prog Lipid Res 2000; 39 (4): 289–314.

    Article  PubMed  CAS  Google Scholar 

  72. Morita I, Schindler M, Regier MK, Otto JC, Hod T, DeWitt DL, Smith WL. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem 1995; 270(18):10,902–10,908.

    Google Scholar 

  73. Bhattacharya M, Peri KG, Almazan G, Ribeiro-da-Silva A, Shichi H, Durocher Y, et al. Nuclear localization of prostaglandin E2 receptors. Proc Natl Acad Sci USA 1998; 95(26):15,792–15,797.

    Google Scholar 

  74. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993; 122: 518–523.

    PubMed  CAS  Google Scholar 

  75. Giardiello FM, Spannhake EW, DuBois RN, Hylind LM, Hubbard WC, Hamilton SR, Yang VW. Prostaglandin levels in human colorectal mucosa: effect of sulindac in patients with familial adenomatous polyposis (FAP). Gastroenterology 1997; 112: A568.

    Article  Google Scholar 

  76. Sheng H, Shao J, Morrow J, Beauchamp RD, DuBois RN. Modulation of apoptosis by prostaglandin treatment in human colon cancer cells. Cancer Res 1998; 58: 362–366.

    PubMed  CAS  Google Scholar 

  77. Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001; 12: 12.

    Google Scholar 

  78. Adam L, Mazumdar A, Sharma T, Jones TR, Kumar R. A three-dimensional and temporo-spatial model to study invasiveness of cancer cells by heregulin and prostaglandin E2. Cancer Res 2001; 61 (1): 81–87.

    PubMed  CAS  Google Scholar 

  79. Watanabe K, Kawamori T, Nakatsugi S, Ohta T, Ohuchida S, Yamamoto H, et al. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 1999; 59: 5093–5096.

    CAS  Google Scholar 

  80. Watanabe K, Kawamori T, Nakatsugi S, Ohta T, Ohuchida S, Yamamoto H, et al. Inhibitory effect of a prostaglandin E receptor subtype EP(1) selective antagonist, ONO-8713, on development of azoxymethane-induced aberrant crypt foci in mice. Cancer Lett 2000; 156: 57–61.

    CAS  Google Scholar 

  81. Sonoshita M. Acceleration of intestinal polyposis through prostaglandin EP2 in APCdelta716 knockout mice. Nature Med 2001; 9: 1048–1051.

    Google Scholar 

  82. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, et al. Combinatorial chemoprevention of intestinal neoplasia. Nature Med 2000; 6: 1024–1028.

    Article  PubMed  CAS  Google Scholar 

  83. Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX, Du BR. Targeting cyclooxygenase 2 and her-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 2001; 120 (7): 1713–1719.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Rajnish A. Gupta PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raymond N. DuBois MD,PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Ohio State University College of Medicine and School of Public Health, Columbus, OH, USA

    Randall E. Harris MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Gupta, R.A., DuBois, R.N. (2003). Cyclooxygenase-2, Prostaglandins, and Colorectal Carcinogenesis. In: Harris, R.E. (eds) COX-2 Blockade in Cancer Prevention and Therapy. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-302-6_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-302-6_10

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-304-6

  • Online ISBN: 978-1-59259-302-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation